Skip to Content

Livalo Approval History

FDA Approved: Yes (First approved August 3, 2009)
Brand name: Livalo
Generic name: pitavastatin
Dosage form: Tablets
Company: Kowa Company, Ltd.
Treatment for: High Cholesterol

Livalo (pitavastatin) is an HMG CoA reductase inhibitor indicated for the primary treatment of hypercholesterolemia and combined dyslipidemia.

Development History and FDA Approval Process for Livalo

DateArticle
Aug  4, 2009Approval FDA Approves Livalo for Primary Hypercholesterolemia and Combined Dyslipidemia
Oct 28, 2008Kowa Announces NDA Submission and MAA Filing for HMG CoA Reductase Inhibitor Pitavastatin

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide